Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
found this, dated Nov15 https://www.chemxpert.in/news/nanosmart-receives-second-fda-orphan-drug-designation-for-treatment-of-pediatric-cancer
From RGBP website to check to see if related
HemaXellerate
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
Fat stem cell based product to treat bone marrow that has been damaged
Bone marrow damage occurs from radiation, chemo, or chronic conditions
HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)
Welcome back Jack.
Dr. Harry Lander, Regen's president and CSO, noted, "Biotechnology companies focused on successful immune-oncology therapies are generally granted trophy value transactions (e.g., deals that have a value in excess of $1 billion). In addition to our intent to create a first-in-class immune checkpoint inhibitor for treating cancers, we also plan to exploit the anti-autoimmune aspects of our small molecules as well. Thus, while we can't anticipate what our valuation will be if our programs pan out, it's good to know we're swimming in the right pool."
Currently CheckPoint Immunology is at the lead optimization phase of its medicinal chemistry program. The Company anticipates that once results of the medicinal chemistry program being conducted by ChemDiv, Inc. are available, we should be in a position to form alliances with large companies interested in NR2F6 inhibition for cancer therapy or NR2F6 activation for treating autoimmune disorders.
Regen BioPharma's Chairman and CEO, David Koos, stated, "In the beginning, Regen's business model was created with the goal of developing intellectual property to a point of attracting large pharmaceutical companies, to participate in maturing Company assets, either by sale, license or co-development. By forming CheckPoint Immunology, we are setting our game plan in place so that as we get further along in our development of small molecule therapies for treating cancer and autoimmune diseases, we can structure a transaction specific to NR2F6-related therapies. The Company has been approached by numerous parties interested in our NR2F6 based therapies. We expect, as we further optimize our small molecule compounds, there should be even greater interest. Hence the reason for creating CheckPoint Immunology is as a pure vehicle for any future NR2F6 transaction."
Wonder if there's still a relationship here?
https://objectivecp.com/our-work/
One has nothing to do with the other jonesin taint.
Its got that smelly smell
If this drops below .0182 support should be found around .0169
The site wants me to subscribe. If you select us patents on section to left and pharmaceuticals section just above it, then scroll down to the ones in parenthesis, select regen biopharma....
U.S. Patent and Trademark Office Releases Regen Biopharma's Patent Application for Reduction of Post-Surgery Cancer Metastasis by Combination of Cannabidiol and NR2F6 Inhibition
PHARMACEUTICAL | Fri 19 Nov 2021Alexandria, Nov. 19 -- U.S. Patent and Trademark Office has released Regen Biopharma's patent application for reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition. Ichim Thomas and Koos David developed the invention. The patent application number is 17/037284. International Patent Cl..
Ill get the link correct.
Is this new? Sorry if it isn't.
https://www.globalipnews.com/assignee
Time to head upward from here, I hope, lol
Found this site with all of RGBP news throughout years. Kind of a timeline...
https://ycharts.com/companies/RGBP/news
Regen biopharma capital llc
https://opencorporates.com/companies/us_mn/4bf8f0ba-5906-ea11-9188-00155d01b4fc
Mr Caven
Todd S. Caven, Managing Partner
Todd S. Caven is an accomplished executive with 25 years of experience in corporate finance, taxation, mergers & acquisitions, corporate valuations and private financing of various types of transactions. In March of 2009, Mr. Caven co-founded Saguaro Capital Partners, an Arizona based firm that raises growth capital for medical device and technology companies throughout the United States. Currently, Mr. Caven is a consultant of Regen BioPharma Inc, a San Diego, California based biotech research firm which has created an impressive volume of intellectual property in the fields of immune oncology and autoimmune disorders.
In 2003, Mr. Caven founded Rock Ridge Enterprises, a Minnesota-based boutique Private Equity firm that focuses on the acquisition of manufacturing, distribution, construction and business services firms in the upper Midwest. Prior to founding Rock Ridge Enterprises, he served as the CFO of Atterro Human Capital Group (formerly Pro Staff), a $500 million privately held firm in the Staffing and Recruiting industry. Prior to Atterro, Todd held senior-level finance and marketing positions at Nordic Track and the Carlson Companies in Minneapolis, Minnesota. He started his career in corporate finance at Amoco Corporation in Chicago, Illinois (now British Petroleum).
Todd earned a Bachelors degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
At least you are in!
Could tap .0193 today, hope not.
"movement" lol
This is probably why cornell is involved.
Ralph Nachman, M.D.
A renown hematologist, is a member of the Institute of Medicine and University Professor and former Chairman of Medicine at NY Presbyterian/Weill Cornell Medical Center. Dr. Nachman, the Lewis Thomas University Professor and Associate Dean of Clinical Research at Weill Cornell Medical College, is a physician, scientist, educator and administrator. Dr. Nachman has pioneered discoveries in hematology and medical oncology that have furthered the development of new clinical solutions to blood and vascular disorders.
Dr. Nachman has spearheaded multiple endeavors in biomedical research, clinical programs, educational curricula, residency training, fundraising, and quality assurance. His discoveries in vascular biology, and the establishment of the Specialized Center of Research (SCOR) in Thrombosis (National Institutes of Health) at New York-Cornell, led to his performing the first culture of human endothelial cells. This achievement initiated a modern explosion of knowledge in vascular biology. He has published numerous articles in the field of hematology and has lectured around the world. His honors include, The Stratton Award from the American Society of Hematology and the Robert Williams, MD Distinguished Chair of Medicine Award from the Association of Professors of Medicine. He is a member of the Institute of Medicine of the National Academy of Sciences.
I sold my couch to buy more rgbp so I am jonesin even more,lol
I did. Where those shares coming from?
Noticed big red also, good school.
How "we" paying for this?
I also take it the BRG report has been submitted to RGBP that's why this was done
tem 8.01 Other Events.
On November 11,2021 Regen Biopharma, Inc. (the “Company”) entered into a Letter of Intent ( “LOI”) with Canary Oncoceutics, Inc (“Canary”) and Canary Oncoceutics Partners, LLC (“LLC”) whereby the Company shall acquire 95% of the share capital and voting power of Canary ( “Canary Controlling Interest”) for consideration consisting of $1,000,000 and common shares of the Company valued at the average share price of the common shares in the 2 weeks prior to the closing of a definitive agreement between the parties (“RGBP Share Value”). The number of common shares to be issued shall be the number of common shares valued at the RGBP share value which shall equal the value of the Canary Controlling Interest as determined by a mutually acceptable third-party valuation expert.
No definitive agreement between the parties for the acquisition by the Company of the Canary Controlling Interest shall close unless the Company shall have raised the amount of $50,000,000 USD dedicated solely to the development and commercialization of Canary diagnostics and products (“Canary Funds”).
It is understood that the IP that will be licensed into Canary will originate from Cornell University. The final IP will be included in the definitive agreement as an appendix. This IP allows for the creation of patient-derived tumor on vascular nets for in vitro testing of therapeutic agents.
It is contemplated by the parties that until the first commercial contract for use of the first Test Product, the Company shall pay to LLC on each anniversary of the effective date of any definitive agreement the applicable fees listed below, with the last year pro-rated:
8k out
Trades kinda nice keeps coming back to consolidation patterns and rides the 50
Not many and none with regulatory filings.
Based on 3,746,423,788 shares issued and outstanding as of May 14,2021
Title of Class Name and Address of Beneficial Owner Amount and Nature of Beneficial Ownership Percentage
Common David R. Koos 2466568 0.07 %
c/o Regen Biopharma, Inc
4700 Spring Street, Suite 304,
La Mesa, California 91942*
All Officers and Directors as a Group 2466568 0.07 %
* includes 3104 shares held by BMXP Holdings Shareholder's Business Trust and 705 shares held by the AFN Trust
Based on 414,147,858 shares issued and outstanding as of May 25,2021
Title of Class Name and Address of Beneficial Owner Amount and Nature of Beneficial Ownership Percentage
Series A Preferred David R. Koos 197788998 4.7 %
c/o Regen Biopharma, Inc
4700 Spring Street, Suite 304,
La Mesa, California 91942*
Zander Therapeutics, Inc. 197785714 4.7 %
All Officers and Directors as a Group 197788988 4.7 %
* includes 316 shares held by BMXP Holdings Shareholder's Business Trust and 71 shares held by the AFN Trust and 197785714 shares held by Zander Therapeutics, Inc. both of which are controlled by David Koos.
Based on 44,000,000 shares issued and outstanding as of 5/25/2021
Title of Class Name and Address of Beneficial Owner Amount and Nature of Beneficial Ownership Percentage
Series M Preferred David R. Koos 11500000 26.14 %
c/o Regen Biopharma, Inc
4700 Spring Street, Suite 304,
La Mesa, California 91942
Series M Preferred Todd S. Caven 10000000 22.73 %
8578 TERRACEVIEW LANE NORTH
MAPLE GROVE, MN 55311
Series M Preferred Roger Formisano 3000000 6.82 %
4124 N. 64th Street
Scottsdale, AZ 85251
Series M Preferred Robert D. Hopkins 3000000 6.82 %
11642 N. 40th Place
Phoenix, AZ 85028
Series M Preferred Harry Lander 10000000 22.73 %
50 SUTTON PLACE SOUTH
APT. 6A
NEW YORK, NY 10022
Series M Preferred Jean-Pierre Millon 6000000 0.136364
3908 E. San Miguel Ave
Paradise Valley, AZ 85253
All Officers and Directors as a Group 11500000 26.14 %
Based on 50,000 shares issued and outstanding as of May 25, 2021
Title of Class Name and Address of Beneficial Owner Amount and Nature of Beneficial Ownership Percentage
Series AA Preferred David R. Koos 50000 100 %
c/o Regen Biopharma, Inc
4700 Spring Street, Suite 304,
La Mesa, California 91942
All Officers and Directors as a Group 50000 100 %
Based on 10,000 shares issued and outstanding as of May 25, 2021
Title of Class Name and Address of Beneficial Owner Amount and Nature of Beneficial Ownership Percentage
Series NC Preferred David R. Koos 10000 100 %
c/o Regen Biopharma, Inc
4700 Spring Street, Suite 304,
La Mesa, California 91942
All Officers and Directors as a Group 10000 100 %
No updates have been done on website.
Yes, it is possible.
Haven't searched all SEC docs, can't piss away my days on RGBP(I am secure in my holding of RGBP, did my homework) while doing the daily grind.
yeppers, I found that months ago, glad i found it again and so did you
Mr. Jean-Pierre Millon, also known as JP, was a Special Limited Partner of Care Capital, LLC and a Co-founder of BLS LLC. Mr. Millon joined PCS Health Systems, Inc. in 1995, where he served as its President and Chief Executive Officer from June 1996 to September 2000. He served as an Executive and held several leadership positions with Eli Lilly and Company including the position of Chief Executive Officer. He was named to that post in June 1996 following a year as Chief Operating Officer of PCS. Mr. Millon’s career with Lilly and its subsidiaries spanned two decades and was highlighted by leadership positions in the United States and executive posts in the Orient, Europe and the Caribbean Basin. Most recently, he served as President and General Manager of Lilly Japan, K.K. and Vice President of the Lilly pharmaceutical division in Kobe, Japan. He directed strategic planning, personnel, Japan business planning and marketing research efforts at Lilly headquarters in Indianapolis. Prior to those corporate directorships, he served as General Manager of the Caribbean Basin in Puerto Rico. He served in financial leadership roles in West Germany, Belgium and France. [color=red][color=red][b]He has been Chairman of Business Advisory Board at Regen BioPharma, Inc. since October 16, 2017. [/color][/color]Mr. Millon serves as the Chairman of the Board of Medical Present Value, Inc. He serves as a Director of Triple Aim Ventures, LLC/TAV Health. He served as the Chairman of Prometheus Laboratories Inc. Mr. Millon served as the Chairman of Protemix Corporation Limited since January 31, 2006. He serves as a Proove Biosciences, Inc., Director of M.P. Video Inc, iPhysicianNet Inc., a Scottsdale, Aeneas Buyer Corp. (also known as Health Systems International, LLC) and CVS Caremark, Inc. He has been a Director of Caremark Rx, L.L.C. since March 2004. CaremarkPCS, LLC since March 2004, InfuSystem, Inc. since September 2005, CVS Health Corporation since March 2007 and Prometheus Laboratories Inc. since March 2003. He serves as a Director of Caremark Rx, Inc. and Portable Genomics Inc. He was Member of Chief Executive Officer Advisory Board at Great Point Partners, LLC since 2006. He has served on a number of public companies’ (INFU, CYPB).He was a Director of Equian, LLC. Mr. Millon served as Lead Director of Cypress Bioscience, Inc., from April 2005 to August 18, 2010 and its Director from March 2004 to August 18, 2010. He is also involved with several not-for-profit organizations, covering health care, higher education and international affairs. He served as a Director of InfuSystem Holdings, Inc. from September 2005 to April 24, 2012. He served on the board of AdvancePCS for three years beginning in October 2000 and was an Advisor and Board Member of AdvancePCS. He is a Member of Northwestern’s J.L. Kellogg Graduate School of Management Alumni Advisory Board, Dean’s Council of 100 of the College of Business at Arizona State University, the Phoenix Symphony Board, the Barrow Neurological Foundation Board of Trustees and the International Advisory Council for the Barrow Neurological Institute. Mr. Millon earned an M.B.A in finance from the Kellogg School of Management at Northwestern University, a degree in Mechanical Engineering from Ecole Centrale de Lyon, France and a degree in Economics from the University of Lyon, France.
what's moving this ?
.0261-.0264 should be bottom or support if it keeps going down